RxDoctor Payments Data

Mikram Jafri, MD

Internal Medicine · Albany, NYNPI 1245518463

Payments from drug & device makers

$997in general payments, 2019–2025

Across 15 payments — averaging $66.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$339
  • Avanir Pharmaceuticals, Inc.$314
  • Acadia Pharmaceuticals Inc$104
  • Sunovion Pharmaceuticals Inc.$99
  • CSL Behring$49
  • Johnson & Johnson$42
  • plus $50 from 3 others

What the payments were for

  • Speaking & faculty fees$202%
  • Food & beverage$97798%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$997 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$85,915
Medicare patients
532
Services billed
934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,123$335,912
XareltoRivaroxaban222$63,305
Trelegy ElliptaFluticasone/Umeclidin/Vilanter85$59,151
JardianceEmpagliflozin191$59,056
OzempicSemaglutide51$52,599
XifaxanRifaximin35$48,477
ArexvyRsvpref3 Antigen/As01e/Pf152$48,290
TrulicityDulaglutide51$46,996
EntrestoSacubitril/Valsartan91$30,011
JanuviaSitagliptin Phosphate109$29,091
SantylCollagenase Clostridium Hist.68$28,374
MounjaroTirzepatide24$23,321
MyrbetriqMirabegron121$22,775
Combivent RespimatIpratropium/Albuterol Sulfate42$21,897
Aripiprazole118$18,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Incruse Ellipta$16$132,468300 claims
Johnson & JohnsonXarelto$42$63,305222 claims
Avanir Pharmaceuticals, Inc.Nuedexta$314$11,38716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →